Nature reviews. Clinical oncology 2024 Dec
Vorasidenib: a new hope or a false promise for patients with low-grade glioma?
Related Questions
The approval for vorasidenib was granted for low-grade astrocytomas, but under certain conditions, it can also be recommended for, for example, anapla...
New comment by Radiation Oncologist at Brown University ( February 27, 2025)
Excellent reference @Minesh!